{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:16:49Z","timestamp":1780525009600,"version":"3.54.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403874"],"award-info":[{"award-number":["82403874"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20241203"],"award-info":[{"award-number":["BK20241203"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024T170397"],"award-info":[{"award-number":["2024T170397"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M741629"],"award-info":[{"award-number":["2023M741629"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105342","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T14:53:31Z","timestamp":1776610411000},"page":"105342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Next-generation in vivo CAR-T expansion strategies: Unlocking durable anti-tumor responses in solid tumors"],"prefix":"10.1016","volume":"223","author":[{"given":"Zefeng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyue","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2963-0888","authenticated-orcid":false,"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2026.105342_bib1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib2","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib3","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6625","key":"10.1016\/j.critrevonc.2026.105342_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105342_bib6","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1021\/acsbiomaterials.4c01039","article-title":"Investigation of folate-functionalized magnetic-gold nanoparticles based targeted drug delivery for liver: in vitro, in vivo and docking studies","volume":"10","author":"Alnasraui","year":"2024","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105342_bib7","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105342_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105342_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41551-023-01143-w","article-title":"Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK\/STAT signalling","volume":"8","author":"Bell","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.critrevonc.2026.105342_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-physiol-021119-034627","article-title":"The acidic tumor microenvironment as a driver of cancer","volume":"82","author":"Boedtkjer","year":"2020","journal-title":"Annu Rev. Physiol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105342_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105342_bib12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41590-023-01543-9","article-title":"Neoantigen-specific stem cell memory-like CD4(+) T cells mediate CD8(+) T cell-dependent immunotherapy of MHC class II-negative solid tumors","volume":"24","author":"Brightman","year":"2023","journal-title":"Nat. Immunol."},{"issue":"8010","key":"10.1016\/j.critrevonc.2026.105342_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.critrevonc.2026.105342_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202302992","article-title":"CAR Gene Delivery by T-cell targeted lentiviral vectors is enhanced by rapamycin induced reduction of antiviral mechanisms","volume":"10","author":"Charitidis","year":"2023","journal-title":"Adv. Sci."},{"issue":"8075","key":"10.1016\/j.critrevonc.2026.105342_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-025-09212-7","article-title":"Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery","volume":"644","author":"Chen","year":"2025","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105342_bib16","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105342_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105342_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217814","article-title":"Investigation of the Impact from IL-2, IL-7, and IL-15 on the growth and signaling of activated CD4(+) T cells","volume":"21","author":"Coppola","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105342_bib19","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","article-title":"Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector","volume":"33","author":"Coradin","year":"2025","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105342_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coi.2010.02.013","article-title":"Inflammatory cytokines as a third signal for T cell activation","volume":"22","author":"Curtsinger","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"issue":"8010","key":"10.1016\/j.critrevonc.2026.105342_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105342_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124779","article-title":"Nanoparticle-mediated universal CAR-T therapy","volume":"666","author":"Fan","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105342_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1500177","article-title":"GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation - successfully treated by extracorporeal photopheresis","volume":"15","author":"Farid","year":"2024","journal-title":"Front. Immunol."},{"issue":"48","key":"10.1016\/j.critrevonc.2026.105342_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202409812","article-title":"Simplified lipid nanoparticles for tissue- and cell-targeted mrna delivery facilitate precision tumor therapy in a lung metastasis mouse model","volume":"36","author":"Fei","year":"2024","journal-title":"Adv. Mater."},{"issue":"51","key":"10.1016\/j.critrevonc.2026.105342_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2518996122","article-title":"Dual-targeted ping-pong CAR T cells: leveraging peripheral expansion to improve solid tumor immunotherapy","volume":"122","author":"Finck","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105342_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178558","article-title":"IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells","volume":"135","author":"Fu","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105342_bib28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.20892\/j.issn.2095-3941.2022.0452","article-title":"Bacterial outer membrane vesicle-based cancer nanovaccines","volume":"19","author":"Gao","year":"2022","journal-title":"Cancer Biol. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105342_bib29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105342_bib30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105342_bib31","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105342_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010709","article-title":"Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma","volume":"13","author":"Herzberg","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"6753","key":"10.1016\/j.critrevonc.2026.105342_bib33","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105342_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.matchemphys.2024.129446","article-title":"Investigation of dextran-coated magnetic nanoparticles encapsulated by medication and modified with folate for targeted drug delivery: Invitro and docking studies","volume":"321","author":"Hussein F Alnasraui","year":"2024","journal-title":"Mater. Chem. Phys."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105342_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166028","article-title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105342_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102937","article-title":"Harnessing cytokine immunocomplexes and cytokine fusion proteins for cancer Therapy: Mechanisms and clinical potential","volume":"136","author":"Kong","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105342_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002151","article-title":"VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding","volume":"9","author":"Lanitis","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105342_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105342_bib39","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41571-025-01075-1","article-title":"Optimizing CAR T cell therapy for solid tumours: a clinical perspective","volume":"22","author":"Li","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105342_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01575-6","article-title":"Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy","author":"Li","year":"2026","journal-title":"Nat. Biomed. Eng."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105342_bib41","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.cell.2025.02.035","article-title":"Engineering sonogenetic EchoBack-CAR T cells","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105342_bib42","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/s41551-024-01272-w","article-title":"Viscoelastic synthetic antigen-presenting cells for augmenting the potency of cancer therapies","volume":"8","author":"Liu","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"6449","key":"10.1016\/j.critrevonc.2026.105342_bib43","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105342_bib44","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105342_bib45","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105342_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.gene.2017.10.015","article-title":"The role of CXCL12 in tumor microenvironment","volume":"641","author":"Meng","year":"2018","journal-title":"Gene"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105342_bib47","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105342_bib48","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41565-021-00982-5","article-title":"Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety","volume":"16","author":"Nguyen","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib49","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s42003-025-08906-y","article-title":"CD28-mediated linear and parallel costimulatory signaling cooperatively regulate CAR-T cell functions via CAR-CD28 microclusters","volume":"8","author":"Nishikawa","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.critrevonc.2026.105342_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-026-10235-x","article-title":"vivo site-specific engineering to reprogram T cells","author":"Nyberg","year":"2026","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105342_bib51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.immuni.2025.01.009","article-title":"vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313","volume":"58","author":"Nyberg","year":"2025","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib52","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"issue":"10432","key":"10.1016\/j.critrevonc.2026.105342_bib53","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105342_bib55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ccell.2025.02.008","article-title":"Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia","volume":"43","author":"Pham-Danis","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","article-title":"From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy","volume":"23","author":"Pinto","year":"2025","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105342_bib57","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","volume":"43","author":"Rakhshandehroo","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"6382","key":"10.1016\/j.critrevonc.2026.105342_bib58","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105342_bib59","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105342_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1411393","article-title":"Engineering strategies to safely drive CAR T-cells into the future","volume":"15","author":"Rossi","year":"2024","journal-title":"Front. Immunol."},{"issue":"6576","key":"10.1016\/j.critrevonc.2026.105342_bib61","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105342_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01508-3","article-title":"Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models","author":"Sasaki","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105342_bib64","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I Anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105342_bib65","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105342_bib66","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"8047","key":"10.1016\/j.critrevonc.2026.105342_bib67","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105342_bib68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2026.105342_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.886637","article-title":"Influence of culture conditions on ex vivo expansion of T lymphocytes and their function for therapy: current insights and open questions","volume":"10","author":"Sudarsanam","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105342_bib70","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105342_bib71","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nbt.4181","article-title":"Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery","volume":"36","author":"Tang","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"6667","key":"10.1016\/j.critrevonc.2026.105342_bib72","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.add7034","article-title":"Probiotic-guided CAR-T cells for solid tumor targeting","volume":"382","author":"Vincent","year":"2023","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105342_bib73","article-title":"Nanomodified switch induced precise and moderate activation of CAR-T cells for solid tumors","volume":"10","author":"Wang","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-024-01986-y","article-title":"MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105342_bib75","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acsnano.6b08731","article-title":"Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated therapy","volume":"11","author":"Wang","year":"2017","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105342_bib76","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.2015.973859","article-title":"mRNA transcript therapy","volume":"14","author":"Weissman","year":"2015","journal-title":"Expert Rev. Vaccin."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105342_bib77","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105342_bib78","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1016\/j.cell.2025.07.046","article-title":"Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy","volume":"188","author":"Wu","year":"2025","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105342_bib79","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib80","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12943-024-02154-0","article-title":"Membrane-bound IL-7 immobilized by the CD8 transmembrane region improves efficacy of CD19 CAR-T cell therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105342_bib81","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol. Ther."},{"issue":"625","key":"10.1016\/j.critrevonc.2026.105342_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105342_bib83","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41596-022-00713-7","article-title":"Nanocarriers based on bacterial membrane materials for cancer vaccine delivery","volume":"17","author":"Zhao","year":"2022","journal-title":"Nat. Protoc."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105342_bib84","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105342_bib85","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression?","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105342_bib86","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s43018-025-00949-8","article-title":"Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors","volume":"6","author":"Zhong","year":"2025","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105342_bib87","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41392-024-02028-3","article-title":"Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors","volume":"9","author":"Zhu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2026.105342_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106454","article-title":"Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor","volume":"184","author":"Zuo","year":"2022","journal-title":"Pharm. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:03:08Z","timestamp":1780038188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":88,"alternative-id":["S1040842826002295"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105342","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation in vivo CAR-T expansion strategies: Unlocking durable anti-tumor responses in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105342"}}